GlassScriptPhysician profile
Pui Yu Hon
NPI 1841683828
$3,233.47
in general payments reported to CMS, 2019-2025
27 companies · $1,390 in 2025
The $1,390 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $169 · 2022: $191 · 2023: $721 · 2024: $762 · 2025: $1,390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,846 · Long Term Medical Supply Or Device Loan: $27.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,846.25 |
| Long Term Medical Supply Or Device Loan | $27.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $297.01 | 2023-2024 | Wavewriter Alpha Prime 16 |
| Amgen INC. | $243.56 | 2025 | Krystexxa, Tavneos |
| Alexion Pharmaceuticals, INC. | $234.26 | 2023-2024 | Strensiq |
| Exeltis, USA INC. | $228.16 | 2021-2023 | Slynd |
| Abbvie INC. | $182.79 | 2021-2024 | |
| Biomerieux INC | $162.00 | 2025 | |
| Fresenius Kabi USA, LLC | $140.84 | 2024 | Kabiven |
| Hologic Sales and Service, LLC | $139.39 | 2024-2025 | Aptima |
| Neurocrine Biosciences, INC. | $138.60 | 2025 | |
| Dexcom, INC. | $135.37 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Kyowa Kirin, INC. | $121.84 | 2025 | |
| Sanofi-Aventis U.S. LLC | $119.62 | 2023 | |
| Amarin Pharma, INC. | $117.34 | 2023 | |
| Phathom Pharmaceuticals, INC. | $112.93 | 2025 | Voquezna |
| Gilead Sciences, INC. | $109.15 | 2025 | Yeztugo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $107.52 | 2024 | Freestyle Libre 3 |
| Coloplast Corp | $95.10 | 2023 | Titan |
| Insmed, INC. | $93.46 | 2025 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.75 | 2025 | |
| Neurelis, INC. | $85.70 | 2023 | Valtoco |
| Ultragenyx Pharmaceutical INC. | $63.00 | 2024 | |
| Scynexis, INC. | $54.68 | 2022 | |
| Biogen, INC. | $40.42 | 2022 | |
| Pfizer INC. | $40.24 | 2025 | |
| Evofem Biosciences, INC. | $32.24 | 2021-2022 | |
| Baxter Healthcare | $27.72 | 2025 | Hillrom - Eli 280 |
| Astellas Pharma US INC | $19.78 | 2023 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pui Hon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.